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Abstract Pre-eclampsia is a multifactorial and multisystemic disease specific to gestation. It is
classically diagnosed by the presence of hypertension associated with proteinuria
manifested in a previously normotensive pregnant woman after the 20th week of
gestation. Pre-eclampsia is also considered in the absence of proteinuria if there is
target organ damage. The present review takes a general approach focused on aspects
of practical interest in the clinical and obstetric care of these women. Thus, it explores
the still unknown etiology, current aspects of pathophysiology and of the diagnosis,
the approach to disease prediction, its adverse outcomes and prevention. Manage-
ment is based on general principles, on nonpharmacological and on pharmacological
clinical treatment of severe or nonsevere situations with emphasis on the hypertensive
crisis and eclampsia. Obstetric management is based on preeclampsia without or
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Pre-eclampsia is a multifactorial and multisystemic disease
specific to gestation that is classically diagnosed by the
presence of hypertension associated with proteinuria man-
ifested in a previously normotensive pregnant woman after
the 20th week of gestation. Currently, pre-eclampsia is also
considered when target organ damage occurs in the absence
of proteinuria.1 The multisystemic nature of pre-eclampsia
implies the possibility of evolution to more severe situations
such as eclampsia, hemorrhagic stroke, hemolysis, elevated
liver enzymes, and a low platelet count (HELLP) syndrome,
renal failure, pulmonary edema, and death.2 Eclampsia refers
to the occurrence of generalized tonic-clonic seizures or
coma in a pregnant woman with pre-eclampsia, and is one
of the most serious complications of the disease.3
A systematic review of data made available between 2002
and 2010 showed an incidence of pre-eclampsia ranging
from 1.2 to 4.2%, and of eclampsia ranging from 0.1 to 2.7%,
with higher rates identified in regions of lesser socioeco-
nomic development.4 It highlights the lack of information on
these important outcomes, especially in places where the
disease is more prevalent.
When evaluating the use ofmagnesium sulfate (MgSO4), a
medication of choice for the prevention or treatment of
eclampsia, Sibai has demonstrated that eclampsia occurred
in between 2 and 3% of pre-eclampticwomenwho developed
signs of severity and did not receive prophylaxis for seizures.
In addition, 0.6% of the patients with pre-eclampsia initially
classified without signs of severity also evolved to eclamp-
sia.5 In Brazil, Giordano et al6 evaluated 82,388 pregnant
women attended at 27 reference maternity hospitals. The
general prevalence reportedwas of 5.2 cases of eclampsia per
1,000 live births, ranging from 2.2:1000 in more developed
areas to 8.3:1000 in less developed areas. In that study,
eclampsia accounted for 20% of 910 cases classified as severe
maternal outcomes.
According to the World Health Organization (WHO),
hypertensive disorders of gestation are an important cause
of severe morbidity, long-term disability, and both maternal
and perinatal mortality. Although 10 to 15% of direct mater-
nal deaths are associated with pre-eclampsia/eclampsia
worldwide, 99% of these deaths occur in low- and middle-
income countries.7 Severe morbidities associated with pre-
eclampsia and eclampsia can lead to death, such as renal
failure, stroke, heart failure, pulmonary edema, coagulop-
athy, and hepatic impairment.8 Fetal and neonatal compli-
cations result mainly from placental insufficiency and the
frequent need for premature delivery that result in high rates
of perinatal morbidity and mortality.9
Etiology
Identifying the exact cause of pre-eclampsia is likely to result
in a significant reduction in maternal and perinatal morbidi-
ty and mortality. However, since its etiology remains un-
known, acting effectively for preventing its development
(primary prevention) is not possible. On the other hand,
there is a constant concern with identifying risk factors for
acting preventively against themanifestation of severe forms
of the disease (secondary prevention).
Attempts to explain the etiology of pre-eclampsia have
resulted in a myriad of hypotheses, although a single expla-
nation for the disease is really unlikely.10–16 Currently, the
most important pathogenesis involves deficient placenta-
tion, genetic predisposition, impaired immune tolerance,
in < 24 weeks, between 24 and less than 34 weeks, and  34 weeks of gestation, and
guidance on route of delivery. An immediate puerperium approach and repercussions








Resumo A pré-eclâmpsia é uma doença multifatorial e multissistêmica específica da gestação. É
classicamente diagnosticada pela presença de hipertensão arterial associada à protei-
núria em gestante previamente normotensa após a 20a semana de gestação. A pré-
eclâmpsia também é considerada na ausência de proteinúria se houver lesão de órgão-
alvo. A presente revisão tem uma abordagem geral focada em aspectos de interesse
prático na assistência clínica e obstétrica dessas mulheres. Assim, explora a etiologia
ainda desconhecida, aspectos atuais da fisiopatologia e do diagnóstico e diagnóstico
diferencial de convulsões, a abordagem da predição da doença, seus resultados
adversos e prevenção. A conduta baseia-se em princípios gerais, tratamento clínico
não farmacológico e farmacológico de situações graves ou não graves, com ênfase na
crise hipertensiva e eclâmpsia. O controle obstétrico se fundamenta na pré-eclâmpsia
sem ou com sinais de deterioração clínica e/ou laboratorial, estratificação da idade
gestacional abaixo de 24 semanas, entre 24 e menos de 34 semanas e 34 ou mais
semanas de gestação e orientação na via de parto. Uma abordagem imediata do
puerpério e repercussões na vida futura de gestantes que desenvolvem pré-eclâmpsia
também foram apresentadas.
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systemic inflammatory response, angiogenic imbalance, and
deficient nutritional status.17,18
To improve the understanding of the pathophysiology of
pre-eclampsia, the most important theories were integrated
into two stages (preclinical and clinical) described by Redman
et al.19 In thefirst stage, changes in the placental development
and insufficient changes in uterine circulation are a result of
hypoxiaof theplacental tissue, andmainlyof thephenomenon
ofhypoxia and reoxygenation, andprovide thedevelopmentof
oxidative stress and of excessive production of inflammatory
and antiangiogenic factors.20 In the second stage, placental
dysfunction and the factors it releases damage the endotheli-
um systemically by resulting in the appearance of hyperten-
sion and in the compromise of target organs. Glomerular
changes (glomeruloendotheliosis) are themost characteristic,
and are responsible for the appearance of proteinuria. Roberts
et al proposed amore complex theory, inwhich they associate
these stages with maternal constitutional factors in the belief
that placental dysfunction per se is not enough to cause the
disease.11 Moreover, since most metabolic alterations of pre-
eclampsia represent an exacerbation of changes observed in
normal pregnancies, in pregnant women with predisposing
factors (obesity,metabolic syndromes,diseases responsiblefor
chronic basal inflammatory response), subtle placental
changes, and even close to normal, may be sufficient to induce
the second stage, that is, the clinical form of the disease.
Despite the unknown etiology of pre-eclampsia, it is
becoming evident that obese women or with high body
mass index (BMI > 30kg/m2) are at a particularly high risk
for developing the disease.21,22 Other changes of risk are
chronic hypertension, pregestational diabetes, and systemic
lupus erythematosus.20,23 The association of pre-eclampsia
with obesity may stem from the chronic state of systemic
inflammation and, as the body mass index (BMI) increases,
the activation of inflammatory pathways at the maternal-
fetal interface is also exacerbated.21,24,25
Diagnosis
The most widespread classification establishes four possible
forms of hypertensive disorders during pregnancy: chronic
hypertension, gestational hypertension, pre-eclampsia-
eclampsia, and chronic hypertension with superimposed
pre-eclampsia.1 Recently, the International Society for the
Study of Hypertension in Pregnancy (ISSHP) has admitted
the possibility of “white-coat hypertension” occurring in the
gestation, as seen in the medical clinic.26 This condition is
characterized by the presence of hypertension ( 140  90
mmHg) during prenatal care, which is not presented in home
evaluations. This form of hypertension should only be consid-
eredwhen present in thefirst half of gestation and should not
be confused with pre-eclampsia, which is specific to
the second half of gestation. However, the “white coat hyper-
tension” is associatedwithworsematernal-fetal outcomesand
is a risk factor for pre-eclampsia. For the current clinical
practice, we consider the four forms described below:
Chronic hypertension: presence of hypertension before
the pregnancy or identified before 20 weeks of gestation.
Pre-eclampsia: manifestation of hypertension after the
20th week of gestation associatedwith significant proteinuria.
Although this association is classically considered, currently,
the presence of proteinuria is not mandatory for the diagnosis
of pre-eclampsia. If hypertension, after the 20th week, is
associated with systemic impairment or target organ damage
(thrombocytopenia, hepatic dysfunction, renal failure, pulmo-
nary edema, imminent eclampsia, or eclampsia), the disease
should be diagnosed even in the absence of proteinuria. The
association of arterial hypertension with signs of placental
impairment, such as fetal growth restriction and/or Doppler
velocimetric changes shouldalso call attention to thediagnosis
of pre-eclampsia, even in the absence of proteinuria.26
Chronic hypertension with superimposed pre-eclamp-
sia: this diagnosis must be established in some specific
situations, namely: 1) after 20 weeks of gestation, there is
onset or worsening of proteinuria already detected in the
first half of pregnancy (the increase must be greater than
three times the initial value); 2) pregnant women with
chronic hypertension who need an association of antihyper-
tensive drugs or an increase in initial therapeutic doses; 3) in
the occurrence of target organ damage.
Gestational hypertension: identification of arterial hyper-
tension after the 20th week of gestation in a previously
normotensive pregnant womanwithout proteinuria or mani-
festation of other signs/symptoms related to pre-eclampsia.
This form of hypertension should disappear up to 12 weeks
after childbirth. If bloodpressure (BP) levels remainelevated, it
should be reclassified as chronic arterial hypertension that
was masked by physiological changes of the first half of
pregnancy. Considering the current concepts about the diag-
nosis of pre-eclampsia, even in the absence of proteinuria, one
must always be aware of the possibility of unfavorable evolu-
tion of cases initially diagnosed as gestational hypertension,
since up to 25% of these patients will present pre-eclampsia
signs and/or related symptoms, thus altering their diagnosis.
The classification of forms of arterial hypertension during
pregnancyrequires thedefinitionof someconcepts, as follows27:
Hypertension: blood pressure value  140 mmHg and/or
90 mmHg measured after a rest period with the patient in a
seated position, appropriate cuff, considering the 1st Korotkoff
sound as the systolic pressure and the 5th Korotkoff sound as
the diastolic pressure (disappearance of heart sound). In cases
of persistence of sounds until the end of cuff deflation, the
muffling of the sound should be considered as diastolic
pressure. In the absence of a suitable cuff, the use of a BP
correction table according to the arm circumference of the
patient is advised. The measurement should be performed at
the level of midpoint of the arm of the patient (►Annex A).
Significant proteinuria: presence of at least 300 mg in
24-hour urine with a trend in favor of replacing the 24-hour
proteinuria test in clinical practice. The urinary protein/
creatinine ratio has sufficient sensitivity to be used in the
identification of significant proteinuria, and is an easier and
lower cost examination. The ratio  0.3 is considered as
altered (units of both proteinuria and creatinine should be
inmg/dL). If it is not possible to determine proteinuria by the
previous methods, the qualitative evaluation of protein by a
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dipstick test can be considered. The presence of 1þ is
considered as the cutoff for the diagnosis of proteinuria, an
identification compatible with  30 mg/dL.1
Pre-eclampsia with signs and/or symptoms of clinical
deterioration: for a long time, patients with pre-eclampsia
were classified as mild or severe based on the presence of
clinical and/or laboratory manifestations demonstrating sig-
nificant involvement of target organs. Recently, stratification
in mild and severe pre-eclampsia has come to be criticized.
Such a concept could bemisleading, as all of the patientswith
pre-eclampsia may unexpectedly evolve with unfavorable
outcomes. On the other hand, when a patient presents the
diagnosis of severe pre-eclampsia, we can inadvertently
induce anticipation of delivery, and sometimes in an iatro-
genic way. Thus, we recommend that patients with pre-
eclampsia should be evaluated for signs and/or symptoms of
clinical and/or laboratory impairment and be promptly con-
ducted accordingly, always considering the possibility of
progressive clinical deterioration. In this context, the main
clinical and laboratory parameters to be treated and moni-
tored are:
• Hypertensive crisis: BP  160 mmHg and/or 110 mmHg
confirmed at 15-minute interval, preferably after a resting
period with the patient seated.
• Signsof imminenteclampsia: in this case, patientspresent a
clear nervous system compromise and report headache,
photophobia, phosphenes, and scotomas. Peripherally, they
present hyperreflexia. The presence of nauseas and vomit-
ing, epigastric pain and/or pain in the right hypochondrium
is very important, since these symptoms are related to
hepatic impairment.
• Eclampsia: development of tonic-clonic seizures in
patients with a diagnostic of pre-eclampsia. Remember
that, in a few cases, eclampsia presents as the initial
condition, especially in patients whose pre-eclampsia
diagnosis was not considered appropriately.
• Hemolysis, Elevated Liver enzymes and Low Platelets
(HELLP) syndrome: HELLP derives from English and refers
to the association of severe Hemolysis, Elevated Liver
enzymes (liver impairment) and Low Platelets (platelets
consumption) in patients with pre-eclampsia. The afore-
mentioned changes are defined as follows: Hemolysis –
presence of schizocytes and echinocytes in the peripheral
blood and/or elevation of lactate dehydrogenase (LDH)
levels > 600 UI/L and/or indirect bilirubin > 1.2 mg/dL
and/or haptoglobin  0.3 g/L; hepatic impairment deter-
mined by elevation of aspartate aminotranferase (AST) and
alanine aminotransferase (ALT) values > twice their nor-
mal value; platelet count defined as < 100.000/mm3.
• Oliguria: diuresis < 500 mL/24h. Oliguria may not be
directly related to renal function impairment, but as a
result of intense liquid extravasation into the third space,
which is easily identified by the presence of generalized
edema (anasarca).
• Acute renal failure: serum creatinine  1.2 mg/dL.
• Thoracic pain: in this case, the pain in the thoracic region
(associated or not to respiration) indicates both endothe-
lial involvement of the lung and heart. This complaint is
often devalued.
• Pulmonary edema: is related to intense involvement of
the pulmonar endothelium associated or not with heart
failure and/or severe hypertension. However, it is more
frequent in these associations.
In 2013, the American College of Obstetricians and
Gynecologists (ACOG) withdrew the levels of proteinuria
(> 5 g/24h) from the pre-eclampsia-related severity crite-
ria.1 In our opinion, the frequent use of proteinuria levels
as a criterion for the anticipation of delivery made this
evaluation controversial. Thus, we recommend that levels
of proteinuria are not completely devalued, but interpreted
in line with maternal clinical and fetal vitality tests, mainly
when >10 g/24h. We reinforce that this parameter should
not be used as a single criterion for the anticipation of
labor.
Early or Late Pre-eclampsia
Considering the gestational age at the clinicalmanifestation of
pre-eclampsia, the disease can be classified as early (< 34
weeks) or late ( 34weeks). These two forms ofmanifestation
of the disease have different etiologies.28,29 Early-onset pre-
eclampsia is generally associated with increased impairment
of the placental development and of the uteroplacental circu-
lation, abnormal Doppler velocimetric evaluation of uterine
arteries, fetuses growth restriction, and worse maternal and
perinatal outcomes.30,31
Late-onset pre-eclampsia is often associated with meta-
bolic syndromes, inflammation, and chronic endothelial
impairment. Thus, its association with obesity and chronic
diseases is common. The evaluation of the uteroplacental
compartment is often within the normal range or changes
little. Maternal and perinatal outcomes are more favorable
mainly because these manifestations are closer to the term,
which does not mean that the disease should be followed-up
with less care.32 Although the incidence of early pre-eclamp-
sia is generally low, in Brazil it accounts for up to 40% of the
cases of pre-eclampsia seen in tertiary centers.
Differential Diagnosis of Seizures
In pregnant women, the manifestation of seizures after the
20thweekof gestation should always be diagnosed initially as
eclampsia. Only after a careful approach, and often after
treatment based on the diagnosis of eclampsia, it may be
necessary to consider other differential causes for the seiz-
ures. The following special situations should be considered
for differential diagnosis:
• Occurrence of pre-eclampsia/eclampsia before the 20th
week of gestation is rare and one should consider the
possibility of association with molar gestation.
• Persistent neurological changes and treatment-refractory
cases suggest anatomical impairment regardless of the
initial cause really being eclampsia. Whenever we face
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seizures cases of difficult control, especially with MgSO4,
stroke should be investigated.
• Suddenly developing neurological signs and symptoms
may include stroke, expansive brain injury, toxic and
metabolic encephalopaties, reversible cerebral vasocon-
striction syndrome, thrombotic thrombocytopenic pur-
pura, and central nervous system (CNS) infection.33
• Seizures without neurological deficits can be triggered by
metabolic abnormalities (hypocalcemia, hyponatremia, and
hypoglycemia), toxins (drug or alcohol withdrawal, drug
intoxication), infection (meningitis, encephalitis, sepsis), or
recent head trauma. However, the absence of neurological
deficits does not exclude an anatomical brain abnormality.
• Gestation is a triggering factor for some disorders associ-
atedwith seizures, such as thrombotic thrombocytopenic
purpura and uremic hemolytic syndrome, which may be
difficult to differentiate from eclampsia associated with
HELLP syndrome. Another clinical disease that may initi-
ate in pregnancy due to neurological manifestations is
systemic lupus erythematosus.
• In summary, investigation with imaging tests is indicated
whenever the patient presents neurological deficit, coma,
seizures that are difficult to control, persistent visual
changes, seizures before 20 weeks of gestational age
without association with gestational trophoblastic dis-
ease and absence of prior diagnosis of epilepsy.
Pre-eclampsia Prediction
The identification of risks of developing a problem iswhatwe
mean by prediction. It is based on assumptions that phe-
nomena will recur on a constant basis. Therefore, the predic-
tion of pre-eclampsia involves several issues, such as gaps in
its pathophysiology, the diversity of clinical forms, and the
heterogeneity among populations. Therefore, we will focus
on what is most effective and has consistent clinical applica-
bility for the Brazilian reality.34
In all contexts, the clinical history should not be under-
estimated, as it provides important data and remains the
effective way to identify pregnant women at greater risk of
developing pre-eclampsia. Regardless of the quantification
of risk, the identification of these conditions should guide the
expansion of prenatal surveillance by avoiding causing un-
necessary anxiety in patients.►Table 1 lists some of themost
associated clinical conditions with the development of pre-
eclampsia and demonstrates the relative risk posed by each
one to contribute to this outcome.
The interpretation of the magnitude of relative risks (RRs)
associated with each of these clinical conditions may be
different according to the experience of each professional,
and risks will be less or more valued. On the other hand,
based on the exposed risks, all of the patients who present at
least one of the characteristics in►Table 1 should receive the
forms of prevention presented in this chapter. According to
the WHO and ISSHP guidelines, special attention should be
given to the adoption of prevention methods in the presence
of the following clinical conditions: antecedent of pre-
eclampsia, chronic hypertension, obesity (BMI > 30), diabe-
tes, renal diseases, autoimmune diseases, antiphospholipid
syndrome, and multiple pregnancies.
Considering the introduction of biomarkers in the context
of predicting pre-eclampsia, there is no evidence that they
should be routinely incorporated, due to of limitations in
sensitivity and to the costs of their incorporation. This
premise includes the Doppler of uterine arteries in the 1st
and 2nd trimesters and the following blood markers: preg-
nancy-associated plasma protein A (PAPP-A), disintegrin and
metalloprotease-12 (ADAM-12), placental protein-13 (PP-
13), uric acid, leptin, homocysteine, soluble fms-like tyrosine
kinase-1 (sFlt-1), and placental growth factor (PlGF), as well
as urinary markers such as albuminuria and calciuria.
Considering the low occurrence of pre-eclampsia in the
general population (2–5%), not all of the predictive tests offer
reasonable sensitivity. Therefore, like the ACOG and the
WHO, our recommendation is to base the prediction of
pre-eclampsia on the clinical history of the patient.1,7
Prediction of Adverse Outcomes in
Pre-eclampsia
Expectant management in patients with pre-eclampsia is
considered in the face of fetal prematurity or of the scarcityof
resources for maternal and newborn support at the place of
care. This decision allows the promotion of fetal lung matu-
rity with the use of corticosteroids and removal of the
pregnant woman to a more qualified center. However, the
time for managing everything, including patient transporta-
tion, can delay actions and favor the worsening of clinical
conditions, especially since decisions are based on subjectiv-
ity. Themathematical model called Pre-eclampsia Integrated
and Estimated Risks (PIERS) was developed with the aim to
reduce uncertainty in these decisions. It offers a predictive
value to evaluate the odds of adverse outcomes within
48 hours of the admission of the patient.35 The PIERS “risk
Table 1 Risk factors related to the occurrence of preeclampsia
Clinical feature Relative risk
Chronic hypertension
(DBP between 80 and 89 mmHg
in 1st prenatal visit)
1.38 1.01–1.87
Age > 40 years and primiparous 1.69; 1.23–2.29
Age > 40 years and multiparous 1.96; 1.34 2.87
BMI > 30 in 1st prenatal visit 2.12; 1.56–2.88




Multiple gestation 2.93; 2.04–4.21
Pre-existing diabetes mellitus 3.56; 2.54–4.99
Previous history of preeclampsia 7.19; 5.85–8.83
Antiphospholipid antibody syndrome 9.72; 4.34–21.75
Abbreviations: BMI, body mass index; DBP, diastolic blood pressure.
Source: Duckitt et al.34
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calculator” is available online at https://pre-empt.bcchr.ca/
monitoring/fullpiers and in a mobile application.
The following adverse events are considered in the PIERS
model: eclampsia, coma, central blindness, retinal detach-
ment, stroke, early placental abruption, coagulopathy, severe
hepatic dysfunction, hepatic hematoma, pulmonary edema,
myocardial infarction, acute renal failure, and ascites. Con-
sidering that these are life-threatening events for pregnant
women, the inclusion of a tool that can guide decision-
making more objectively seems to be fundamental in terms
of maternal and fetal protection. ►Fig. 1 illustrates the
calculator and how to use it. The decision will be according
to the care scenario, but the transportation of a 1.5% risk
patient will be completely different if the calculated value is
26.5% (►Fig. 1).
Prevention of Pre-eclampsia
Initially, we list the interventions that do not reduce the risk of
pre-eclampsia; hence, they should not be applied in clinical
practice. There is no reason to guide rest, salt restriction in the
diet, use of antioxidants (vitamins C, E), vitaminD, omega-3 or
enoxaparin for the prevention of pre-eclampsia.
The recommended interventions that may result in re-
duced risk of developing pre-eclampsia are the use of ace-
tylsalicylic acid (ASA) and calcium supplementation.36,37
The administration of a daily low dose of ASA (100 to 150
mg) is recommended for patients identified with a risk
factor, according to the guidelines described above on the
prediction of pre-eclampsia. Acetylsalicylic acid should be
given as early as possible (before the 16th week), at night. It
seems reasonable to start at around 12 weeks, even though
there is no associated risk if it is started before that. It can be
maintained until the end of the gestation, but suspension
after the 36th week seems a rational conduct, because it
allows the renewal of platelets with full functional capacity
for the demands of childbirth.
Regarding calcium (Ca) supplementation, a systematic
review concluded that, in general, it results in a 55% reduc-
tion in the risk of pre-eclampsia. This effect is even greater in
women with low-Ca diet and results in a 74% reduction. In
women with a risk factor for pre-eclampsia, this reduction
may reach 78%. During pregnancy, all women should be
instructed to eat a high-Ca diet, and for those at risk for
pre-eclampsia and/or on a low-Ca diet, supplementation of
1.0 to 2.0 g/day is recommended (divided into 2 or 3 doses).
Some rules must be followed for proper completion of the
calculator.
The figure to the side shows an example of data insertion
and the resulting risk. Some additional information:
1 – Gestational age in weeks and days. For full weeks,
      add “0”. For example, fill in 22 weeks 0 days.
2 – If no oximeter is available, assume 97% saturation.
3 – For creatinine, use dot and not comma. Example 2.5
    mg/dl and not 2,5 mg/dl.
4 – Attention  to  the  units.  There  are  two  alternatives:
    Imperial Unit (IU) and International Standard (SI).
  For the Brazilian system use SI.
Fig. 1 Full Pre-eclampsia IntegratedandEstimatedRisks (PIERS) calculator withexampleof a clinical situation, laboratory dataand the resulting calculation.
Some rulesmust be followed for proper completion of the calculator. The figure to the side shows an example of data insertion and the resulting risk. Some
additional information: 1–Gestational age inweeksanddays. For fullweeks, add “0.” Forexample,fill in22weeks0days. 2–If nooximeter is available, assume
97% saturation. 3–For creatinine, use dot and not comma. Example 2.5 mg/dl and not 2,5 mg/dl. 4–Attention to the units. There are two alternatives:
Imperial Unit (IU) and International Standard (SI). For the Brazilian system use SI.
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The interventions discussed so far refer to the prenatal care
scenario, and preventive actions are not limited to “prevent-
ing” the occurrence of pre-eclampsia, but also to reduce the
risk of progression tomore severe forms (tertiary prevention).
Magnesiumsulfate (MgSO4) shouldbe included in this issue, as
it is admittedly the best alternative for the prevention and
treatment of eclampsia. Thismedication should be available in
all maternal-fetal care services, even in primary care settings.
The use of MgSO4 is always recommended in the case of
imminent eclampsia, as well as in a liberal way in patients
with pre-eclampsia with signs of severity, especially for those
with difficult-to-control BP and HELLP syndrome. Finally,
MgSO4should always be administered in the face of situations
whose clinical perception does not rule out the possibility of
evolution to more severe forms or eclampsia.
Management
General Principles
The search for the pre-eclampsia diagnosis is essential.
In prenatal care, attention should be given to weight
gain, especially when it happens quickly and is associated
with hand and face edema, and with increased pressure
levels and reports to signs or symptoms of target organ
involvement.
In the case of the diagnosis of pre-eclampsia, the focus
of clinical control is the prevention of maternal and peri-
natal morbidity and mortality through the following:
guidelines on signs of disease involvement, referral and
care in tertiary services with qualified neonatal care, good
BP control, prevention of eclampsia or its recurrence, and
early identification of laboratory abnormalities, especially
those related to HELLP syndrome. The evaluation of fetal
well-being is also recommended. The combination of these
actions should enable the conduction of cases with the
objective of performing the delivery, the only real way to
avoid the immediate progression of the disease with
balance between maternal-fetal repercussions and the
impact of prematurity.
In the case of eclampsia, basic principles of conduct are
considered, namely, avoid trauma from falls, maintain air-
way permeability and ensure oxygen support, and prevent
aspiration in case of vomiting. Position the pregnant woman
in left lateral or semi-sitting position in bed with lateral
grids, use a Guedel cannula, provide nasal oxygen 5 L/min,
and obtain venous access promptly.
Nonpharmacological Treatment
Diet
A normal diet is recommended without salt restriction,
since there is no evidence supporting this recommendation
for BP control or prevention of adverse outcomes. These
patients must be reminded that they may need long periods
of hospitalization, as well as of the importance of main-
taining the minimum quality of their diet. The restriction in
sodium intake contributes negatively to reduce intravascu-
lar volume.1,38
Hospital or Home Rest
In spite of suggestions that reducing physical activity improves
uteroplacental blood flow and prevents exacerbation of hyper-
tension, particularly if BP is not well controlled, there is no
evidence that it significantly improves the main maternal and
perinatal outcomes. Thus, there is no reason to recommend
absolute rest in patients with pre-eclampsia.39
Laboratory Follow-up
The diagnosis of pre-eclampsia requires follow-up with
laboratory tests for the early identification of target organ
involvement and the diagnosis of HELLP syndrome in its
early stages (only laboratory abnormalities without clinical
signs and symptoms). The frequency of follow-up depends
on the evolution and severity of each case, but the general
recommendation is once a week. Values of hemoglobin,
platelet counts, lactate dehydrogenase (LDH), total bilirubin
or haptoglobin (gold standard for microangiopathic anemia),
creatinine, and ASTshould be evaluated. Note that: 1) there is
no need for repeated evaluations of proteinuria; 2) urea
concentration should not be performed if there is no clear
renal involvement or suspected uremic hemolytic syndrome;
3) for evaluation of hepatic impairment, the dosage of AST
alone is enough; 4) Although uric acid concentration corre-
lates with adverse outcomes, it is not a single marker for
clinical decisions.
Hospital or Outpatient Follow-up
The degree of unpredictability of pre-eclampsia can justify
the continuous hospital follow-up. Long periods of hospital-
ization are not easy for patients and their families, and
overload hospital beds. Thus, hospitalization is recommen-
ded as soon as there is a strong suspicion or diagnostic
confirmation of pre-eclampsia for the proper evaluation of
maternal-fetal conditions, for the introduction/adjustment
of an antihypertensive dose, and for the guidance of the
patient and of her family members about the problem, the
risks, and the types of complications. After an initial period
thatmay vary for each patient, “permits”may be granted and
the patient can intercalate periods of hospitalization (or
hospital evaluation) and periods at home. Well-structured
services with a specific outpatient clinic, especially those
with day hospital programs, are perfect for such cases. The
decision for hospital or outpatient follow-up will depend
heavily on the sociocultural conditions of the patient, and
when identifying any problems that may compromise the




The decision to introduce antihypertensives should consid-
er the risks and benefits for the mother and the fetus, and
take as main factors the value of the BP and the presence or
absence of signs and/or of symptoms. Chronic hypertensive
patients often tolerate elevated BP levels without present-
ing any clinical manifestations. In contrast, young patients
Rev Bras Ginecol Obstet Vol. 41 No. 5/2019
Pre-eclampsia/Eclampsia Peraçoli et al.324
with previous low BP levels may progress to severe con-
ditions and eclampsia even with slightly high levels of BP.
When considering the need for drug treatment, the initial
recommendation for classification of BP during pregnancy
is the following:
Mild hypertension: systolic BP  140 mmHg and < 150
mmHg and/or diastolic BP  90 mmHG and < 100 mmHg
Moderate hypertension: systolic BP between  150
mmHg and < 160 mmHg and/or diastolic BP  100 mmHg
and < 110 mmHg
Severe hypertension: systolic BP  160 mmHg and/or
diastolic BP  110 mmHg
There is a consensus that cases of severe hypertension,
also referred to as hypertensive crisis, should be treated
promptly, and patients should be admitted to and/or referred
to referral centers to investigate target organ involvement
and fetal conditions.
Regarding the use of antihypertensives for the treatment
ofmild tomoderatehypertension levels, themajor concern is
the excessive and/or abrupt reduction of BP. This concern
originates from the fact that, although the reduction of BP
improves circulatory systemic conditions, little effect is
obtained with respect to uteroplacental circulation. The
difficulties to maintain perfusion of this compartment in
the face of an aggressive reduction of systemic BP could
contribute negatively to fetal nutrition and/or oxygenation.
In meta-analyzes of randomized trials that considered the
antihypertensive treatment of pregnant womenwithmild to
moderate hypertension and the recent Control of Hyperten-
sion in Pregnancy Study (CHIPS) trial, increased growth
restrictions or other adverse perinatal outcomes were not
found.40–42 These data contrast with an earlier meta-analysis
that evaluated the effect of antihypertensive therapy on fetal
weight and concluded that the reduction of 10 mmHg in the
mean BP was associated with a reduction of 176 g in birth
weight.43 We believe this controversial point was better
studied in the CHIPS trial, in which a more rigorous treat-
ment of BP for maintaining diastolic BP levels around 85 mm
Hg prevented the occurrence of severe hypertension and
exerted maternal protective factor without promoting fetal
risks.42
All of the antihypertensive drugs cross the placental
barrier, but the agents listed below (►Tables 2 and 3) present
an acceptable safety profile during pregnancy. The choice of
each one will depend on the familiarity of each obstetrician
with them and the possible form of administration in each
situation, that is, oral or intravenous.
Since hypertensive crisis treatment is imperative, anti-
hypertensives should be introduced whenever the BP
reaches  150 mmHg and/or 100 mmHg levels,  140
mmHG and/or 90 mm Hg persistent levels, or if the patient
is symptomatic. In line with these recommendations, the
ISSHP agrees and recommends the treatment goal is main-
taining diastolic BP levels  85 mm Hg.26
Mild to moderate hypertension
►Table 2 presents the antihypertensives recommended for
use in mild to moderate hypertension in pregnant women.
Choices should be based on the degree of experience/familiar-
ity presented by the professional prescribing the medication.
Angiotensin-converting enzyme inhibitors (ACEI), angio-
tensin II receptor blockers (ARB II) and direct renin inhibitors
(Aliskiren) are contraindicated in pregnancy, because they
Table 2 Antihypertensives recommended for use in pregnancy


















10 mg and 20 mg
20 to 120 mg/day
1 to 3x/day
Amlodipine
2.5 mg, 5 mg,
and 10 mg tablets









25 mg, 50 mg,
and 100mg tablets





12.5 to 50 mg/day
1 to 2x/day
Recommendation
is to start with
12.5 mg/day for
2 days and then
increase the dose
We recommend these medications as the third drug for the association
of medications for blood pressure control or if drugs of first choice are
unavailable. β-blockers with the highest clinical experience are labetalol
and pindolol, but the former is not produced in Brazil and the latter has
recently been withdrawn from the market.
Table 3 Agents recommended for the treatment of hypertensive
crisis in pregnant women












Ampoule of hydralazine contains 1 mL at a concentration of
20mg/mL. Dilute one ampoule (1mL) in 19mL of distilled water,



















The sodium nitroprusside ampoule contains 2mL at the
concentration of 50 mg/2mL. Dilute one ampoule (2mL) in
248 mL of 5% glycosated serum, thus obtaining a
concentration of 200 mcg/mL.
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are associatedwith abnormalities in the development of fetal
kidneys when used from the 2nd trimester of gestation on.
Patients should be instructed to discontinue and/or replace
this type of medication in the 1st trimester as soon as they
confirm the pregnancy. However, it is important to reassure
these patients about the use of medications in the beginning
of pregnancy, since these drugs are not teratogenic but
fetotoxic, and offer no risks of malformation with the use
in the 1st trimester.44 Still, the ideal planning for such cases is
preconceptional guidance.
Aspects related to the use ofdiuretics indicate controversies
in the role of thiazide diuretics, although some guidelines
suggest these agents may be maintained in women with
chronic hypertension who used them before pregnancy.26,45
These guidelines are based on the fact that the reduction in
circulatory volume, which occurs in the first weeks, by the use
of these drugs, would probably not occur in this situation
(assuming that drug dose and sodium intake will be constant
throughout the pregnancy). The use of diuretics in chronic
hypertensivepregnantwomenshouldbe interrupted if there is
a reduction in the volume of amniotic fluid (oligoamine) or
superimposed pre-eclampsia, since this condition in itself
determines contraction of circulatory volume. Exceptions are
made for cases of acute pulmonary edema or of renal im-
pairment, inwhich cases the diuretic of choice is furosemide.39
Severe Hypertension
The aim of treatment is to reduce the BP by 15 to 25% and to
reach systolic BP values between 140 mmHg and 150 mmHg,
and diastolic BP values between 90 mmHg and 100 mmHg.
Regardless of the antihypertensive used, abrupt drops in BP
should be avoided due to maternal risks (stroke, infarction)
and risks of reducing the uteroplacental perfusion too much,
thus increasing the negative effects on the fetal well-being.2
Once the desired reductions in systolic and diastolic pressures
are obtained, the use of oralmaintenance antihypertensives is
initiated or optimized rapidly (►Tables 3 and 4).
Hydralazine
Hydralazine is a peripheral vasodilator widely used in the
pre-eclampsia situation for the acute treatment of severe
hypertension.46 Its maximum action occurs in 20 minutes,
and BPmonitoring should be rigorous, since there are risks of
hypotension that should be promptly corrected with eleva-
tion of the lower limbs and removal of medications or factors
that may be acting potentiators. If the return of the BP is not
achieved, careful hydration is recommended.
Nifedipine
Immediate-release oral Nifedipine, a calcium channel block-
er, can also be used as first-line therapy, especially when
intravenous access is not available.47 Its maximum action is
between 30 and 40 minutes, tablets should not be chewed,
and formulations should not be used sublingually.
Sodium Nitroprusside
Sodium nitroprusside is a potent arterial and venous vasodi-
lator. Limited clinical experience and fears about the poten-
tial for fetal cyanide poisoning have long restricted the use of
nitroprusside in pregnancy. However, there is no evidence to
support fetal risk, especially in cases of short-term use (6 to
12 hours). Nitroprusside is especially recommended for
pregnant women with pulmonary edema associated with
cardiac functional impairment, since it exerts important
benefits in both post- and preload.48–50
Magnesium Sulfate
Since the publication of results of The Collaborative Eclamp-
sia Trial – Magpie Trial, MgSO4 is considered the drug of
choice for the treatment of immiment eclampsia and of
eclampsia.51 Systematic reviews indicate that magnesium
sulfate is safer andmore effective than phenytoin, diazepam,
or lithic cocktail (chlorpromazine, prometazine and pethi-
dine) for preventing recurrent seizures in eclampsia, in
addition to being low-cost, easy to administer and not
causing sedation.52–54 Recently, fetal exposure to magne-
sium sulfate therapy has been shown to be a useful weapon
in reducing cases of cerebral palsy and severe motor dys-
function in preterm infants (< 32 weeks of gestation).3
Therefore, the use of magnesium sulfate is highly recom-
mended for cases of imminent eclampsia, eclampsia, HELLP
syndrome (15% of these patients develop eclampsia), and
pre-eclampsia with clinical and/or laboratory deterioration,
including difficult-to-control hypertension (►Table 5).
The Pritchard and the Zuspan schemes are the main ones
for the use of magnesium sulfate. They must be adopted
Table 4 Recommended infusion regimen for sodium nitroprusside
Desired dose (mcg/Kg/min) 0.5 1.0 2.0 3.0 4.0 5.0
Patient weight 50 kg 7.5 15.0 30.0 60.0 90.0 120.0 Infusion rate
(mL/h)60 kg 9.0 18.0 36.0 72.0 108.0 144.0
70 kg 10.0 21.0 42.0 84.0 126.0 168.0
80 kg 12.0 24.0 48.0 96.0 144.0 192.0
90 kg 14.0 27.0 54.0 108.0 162.0 216.0
100 kg 15.0 30.0 60.0 120.0 180.0 240.0
From the practical point of view, recommendation is to start with the minimum dose and increase 1 mL/h every 10 minutes. # When necessary, the
maximum dose should not be used for > 10 minutes, then, reduced by half. The nitroprusside stops acting 3 minutes after the interruption of the
infusion.
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according to the experience of each service, since they are
equally effective.
Magnesium sulfate heptahydrated (MgSO4.7H2O) should
be used with attention to the available concentration of
magnesium:
– MgSO4 50% - 10 mL ampoule contains 5 g of magnesium
– MgSO4 20% - 10 mL ampoule contains 2 g of magnesium
– MgSO4 10% - 10 mL ampoule contains 1 g of magnesium
Aspects Related to the Use of Magnesium Sulfate
The obstetrician should not be afraid about the use ofMgSO4,
since chances of complications related to this medication are
rare, and failing to administer it will be much more reckless
than any risk from it. A few precautions need to be followed:
– If it is necessary to refer the pregnant woman to another
service, the preferential scheme is the intramuscular
(Pritchard), since it is safer for the transportation.
– The therapeutic concentration of the magnesium ion
varies from 4 to 7 mEq/L (4.8 to 8.4 mg/dL), the patellar
reflex is abolished with 8 to 10 mEq/L, and there is risk of
respiratory arrest from 12 mEq/L. A properly adminis-
tered initial dose does not pose a risk of intoxication.
Subsequently, the following parameters should be moni-
tored to maintain the intravenous dose or apply a new
intramuscular dose: patellar reflex present, respiratory
rate  16 irpm and diuresis  25 mL/h. If any changes
occur in these parameters, reduction or interruption of
intravenous infusion and non-performance of intramus-
cular dose are recommended. Then, the concentration of
MgSO4 and renal function are determined. If values are
within the limits of normality, the treatment should be
restarted. Calcium gluconate (1 g intravenously – 10 mL
10% – slowly administered) should be used in cases of
signs of magnesium poisoning.
– In cases of recurrent seizures, 2 g of MgSO4 is adminis-
tered intravenously (bolus) and the dose of 2 g/h is used as
maintenance. If two of these bolus do not control seizures,
the drug of choice will be phenylhydantoin in its classic
regimen for treatment of seizures. In these cases, it is also
recommended to investigate brain complications, mainly
intracranial hemorrhages.
– In patients with renal impairment (creatinine1.2 mg/dL),
the maintenance dose should be half the recommended
dose. Infusionofmagnesiumsulfate shouldbediscontinued
only if diuresis is < 25 mL/h.
– The maintenance of MgSO4 is recommended for 24 hours
after the resolution of gestation or after the last seizure.
Obstetric Management
Pre-eclampsia without Signs of Clinical and
Laboratory Deterioration
According to the best evidence, we recommend the expec-
tant management only up to 37weeks of gestation. From this
moment on and whenever pre-eclampsia is diagnosed at
term, the resolution of gestation is indicated, thereby reduc-
ing maternal risks without altering perinatal outcomes.55–57
Obviously, it is necessary to:
– Maintain control of BP;
– Monitor signs and symptoms of imminent eclampsia;
– Periodically monitor laboratory changes (hemogram, re-
nal and hepatic function). Weekly reassessment or in the
face of clinical changes and/or of uncontrolled BP is
recommended;
– Maintain monitoring of fetal well-being and growth. The
combination of biophysical (mainly cardiotocography)
and hemodynamic (Doppler velocimetry) evaluations is
recommended. However, different centers may follow
specific protocols based on the availability of evaluation
methods.
Pre-eclampsia with Signs or Symptoms of Clinical and/
or Laboratory Deterioration
It is important to keep in mind that signs and symptoms of
severity of pre-eclampsia are often transient. Arterial hyper-
tension itself is an example, since after being controlled, it
can remain stable for a variable time. Thus, it is always
prudent to institute the pertinent treatment for each case
and reassess the patient clinically and laboratorially before
proceeding with the indication of delivery.
Table 5 Magnesium sulfate scheme for prevention and treatment of eclampsia




4 g intravenously (bolus) administered
slowlya þ 10 g intramuscularly
(5 g on each buttock)b
5 g deep intramuscularly every 4 hoursb
Zuspan scheme
Exclusively intravenous
4 g intravenously (bolus)
administered slowlya
1 g intravenously per hour in
continuous infusion pump (CIP)c
aPreparation of intravenous loading dose: MgSO4 50% - 1 ampoule contains 10mL with 5 g of MgSO4.
Dilute 8 mL of MgSO4 50% (4 g) in 12 mL of distilled water or saline solution. The final concentration will be 4 g/20mL. Infuse the solution
intravenously slowly (15–20 minutes).
Another possibility: dilute 8 mL in 100 mL of saline solution 0.9%. Infuse in continuous infusion pump at 300 mL/h. The total volume will be infused in 
20 minutes.
bPreparation of maintenance dose – Pritchard scheme: Use 10 mL of the 50% MgSO4 ampoule. Other presentations should not be used for this
regimen due to their excessive volume.
cPreparation of maintenance dose – Zuspan scheme: Dilute 10mL of 50% MgSO4 (1 ampoule) in 490 mL of 0.9% saline solution. The final
concentration will be 1 g/100mL. Infuse the solution intravenously at the rate of 100 mL per hour.
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Within this context, the clinical deterioration situations




– Hypertension refractory to treatment with three antihy-
pertensive drugs;
– Pulmonary edema/cardiac involvement;
– Progressive laboratory abnormalities (thrombocytopenia,
elevation of liver enzymes);
– Renal insufficiency assessed mainly by progressive eleva-
tion of urea and creatinine levels, oliguria, and anasarca;
– Changes in fetal well-being.
Gestational Age Less than 24 Weeks
At this gestational age, expectant management is associated
with high perinatal mortality (> 80%) and maternal morbid-
ity and mortality (27–71%).58,59 Therefore, in the case of
clinical deterioration, the interruption of the gestation is
recommended, since neonatal viability is low and associated
with several complications and sequelae. Of course, such a
decision should be shared with the patient and her family.
Even with the interruption of gestation, maternal care must
be maintained. Recommendations are the following:
To maintain adequate BP control;
To use MgSO4;
Watch for signs and symptoms of imminent eclampsia;
To maintain laboratory monitoring according to each case
(platelet count, renal and hepatic function).
Gestational age equal to or above 24 weeks and less
than 34 weeks
As the burden of prematurity is very high at this stage, the
resolution of gestation should only occur if the patient fits
the aforementioned changes. Guidelines for these cases are:
To maintain adequate BP control;
To use MgSO4. If there is no absolute indication for
delivery, medication can be given for 24 hours or accord-
ing to the clinical evaluation;
Watch for signs and symptoms of imminent eclampsia;
Maintain laboratory monitoring according to each case
(platelet count, renal and hepatic function);
Monitoring of the well-being and growth of the fetus;
The combination of biophysical (mainly cardiotocogra-
phy) and hemodynamic (Doppler velocimetry) evaluations is
recommended. Different centers may follow specific proto-
cols based on the availability of the methods used:
– Corticosteroid therapy for fetal lung maturation
Betamethasone (12 mg/intramuscularly every 24 hours/
for 48 hours) or
Dexamethasone (6 mg/ intramuscularly every 12 hours/
for 48 hours).
The drug of choice is betamethasone, and dexamethasone
should be used only in the absence of betamethasone. In
these cases, the use of MgSO4 also acts on fetal neuro-
protection and should be used for this purpose at gestational
ages between 24 and < 32 weeks. Even in cases of absolute
indication for the resolution of the gestation, maternal
clinical stabilization is mandatory, especially with the intro-
duction of MgSO4.
Gestational Age between 34 and 37 Weeks
The conduction of these cases is the same as that described
for gestational ages between 24 and 34 weeks. Although
prematurity-related complications are shorter after
34 weeks, they still exist, so in the face of clinical and
laboratorial improvement of the mother, and preserved fetal
vitality, it is recommended to postpone delivery to the
nearest term.56
Delivery Route
The delivery route is based on the obstetric indication.
Transpelvic delivery is always desired, both in prematurity
and at term, and it is possible to perform the procedures of
the preparation of the cervix in the presence of preserved
fetal vitality. However, in cases of pre-eclampsiawith clinical
and/or laboratorial deterioration and unfavorable cervix, we
often find ourselves in situations of poor safety to await the
evolution of delivery labor; therefore, cesarean section is
justified. The procedure is also justified by changes in fetal
vitality.
In cases of pre-eclampsia without signs of deterioration,
evidently at termwith unfavorable cervix, the preparation of
the cervix with misoprostol or with a Foley catheter is
indicated in order to obtain greater success with vaginal
delivery. Special attention is advised in cases of oxytocin use,
as this medication promotes water retention and hypona-
tremia; therefore, concentrated solutions and 0.9% saline
solution should be used. This way, the water supply and
sodium concentrations are maintained. An alternative is to
use 10 UI of oxytocin in 500 mL of saline, starting infusion
with 12mL/h. Theflowchart below is an attempt to guide the
management of cases by associating of maternal clinic and
the assessment of fetal vitality (►Fig. 2).
In HELLP syndrome, when cesarean delivery is indicated
and the platelet count is < 50,000/mm3, the following pre-
cautions are recommended:
– evaluate coagulogram;
– perform general anesthesia;
– replace platelets in the surgical procedure. Usually, five
units are enough;
– perform hemostasis carefully.
Puerperal Care
In the immediate puerperium, it is necessary to:
– Monitor the BP every 4 hours, or more frequently accord-
ing to specific cases. It is prudent to suppress the noctur-
nal BP evaluation if the patient is controlled to allowher to
rest, given the complex initial activity of the maternity
that has just started.
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– Avoid using nonsteroidal anti-inflammatory drugs to
control pain, especially in patients with impaired renal
function and/or with significant blood loss that may have
caused renal impairment.
– Avoid using medications intended to suppress lactation,
such as bromoergocriptine and cabergoline, since they are
associated with increased risk of cerebrovascular events.
– In cases of use of magnesium sulfate, maintain themedica-
tion for 24h. If the patient has difficult-to-control BP and/or
signs and symptoms of imminent eclampsia, magnesium
sulfate should also be used in the puerperium due to the
persistent risk of seizures, especially in the first five days.
– The maintenance or introduction of antihypertensive
drugs in the immediate puerperium is recommended
especially in severe cases, unless the BP is < 110  70
mmHg. In addition to the antihypertensives recom-
mended during pregnancy, medication prohibited for
use in pregnancy is now allowed.
– In severe hypertension, follow the recommendations
already given during gestation.
– Attention to clinical and/or laboratory deterioration. Lab-
oratory reassessment is recommended within 24 hours
postpartum, and new tests will be requested according to
each case.
– Patients with pre-existing hypertension, who used anti-
hypertensive medication and used to have good BP con-
trol, should restart it immediately after delivery if there is
no contraindication to breastfeeding. If the patient
reports poor BP control with the previous medication, it
should be replaced. However, do not introduce diuretics
in the puerperal period given the risk of reduction of
vascular volume and compromise of breastfeeding.
– Patients with chronic kidney disease need to be guided
according to recommendations of the nephrologist.
– Hospital monitoring is recommended until at least the




















































Fig. 2 Flowchart for conductingpreeclampsia cases. Altered fetal vitality is definedby thepresenceofDoppler velocimetryof umbilical arterieswith zeroor
reverse diastole and/or ductus venosus pulsatiliti index – PI > P95 according to gestational age and/or cardiotocography considered abnormal.
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dynamics and water reabsorption into the intravascular
volume usually reestablish between the 3rd and 5th days.
Thus, early discharges do not allow adequatemonitoring of
these events.
– Even after hospital discharge, patients need to be advised
of the possibility of complications and undergo reassess-
ment in  7 days.
– All of the patients who had pre-eclampsia should be
advised of the risk of developing cardiovascular and renal
diseases. The potential negative impact throughout the
life of the woman demands a better multidisciplinary
follow-up, including control of the BP, of the renal func-
tion, and of the lipid and glycemic profiles,60 as well as
lifestyle change (physical activity, balanced diet).
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Annex A Correction of blood pressure according to the







20 þ 11 þ7
22 þ 9 þ6
24 þ 7 þ4
26 þ 5 þ3












Source: Maxwell et al61 and Secretaria de Estado da Saúde de São
Paulo.62
Erratum: The names and affilations havebeen corrected as per Erratumpublished on February 11, 2020.
DOI of the Erratum is 10.1055/s-0040-1702167.
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